China FDA Generic Rejections Show Tightening Quality Noose
This article was originally published in PharmAsia News
Executive Summary
The recent rejection of 11 new drug applications by the China FDA is indicative of the country’s increasingly tightening controls over product quality, with a particular focus on generics, and followed the agency’s newly issued generic drug quality guidance designed to ensure the consistent evaluation of generic filings.